These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 9433640)
21. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. Wolf MS; Fitzner KA; Powell EF; McCaffrey KR; Pickard AS; McKoy JM; Lindenberg J; Schumock GT; Carson KR; Ferreira MR; Dolan NC; Bennett CL J Clin Oncol; 2005 Dec; 23(34):8877-83. PubMed ID: 16314648 [TBL] [Abstract][Full Text] [Related]
22. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. Knudsen AB; McMahon PM; Gazelle GS J Clin Oncol; 2007 Jan; 25(2):203-8. PubMed ID: 17210941 [TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068 [TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening. Ting J; Smith JS; Myers ER J Low Genit Tract Dis; 2015 Oct; 19(4):333-9. PubMed ID: 26225945 [TBL] [Abstract][Full Text] [Related]
25. [Cost effectiveness of human papilloma virus testing in cervical cancer screening: a literature review]. Mejía A; Salas W Biomedica; 2008 Mar; 28(1):160-72. PubMed ID: 18645671 [TBL] [Abstract][Full Text] [Related]
27. Efficacy, effectiveness and cost-effectiveness of endoscopic screening methods. Brenner H Z Gastroenterol; 2008 Apr; 46 Suppl 1():S20-2. PubMed ID: 18368634 [TBL] [Abstract][Full Text] [Related]
28. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. Goldie SJ; Kohli M; Grima D; Weinstein MC; Wright TC; Bosch FX; Franco E J Natl Cancer Inst; 2004 Apr; 96(8):604-15. PubMed ID: 15100338 [TBL] [Abstract][Full Text] [Related]
29. Screening for colorectal cancer: what are the costs? Weller D; Moss J; Hiller J; Thomas D; Edwards J Int J Technol Assess Health Care; 1995; 11(1):26-39. PubMed ID: 7706012 [TBL] [Abstract][Full Text] [Related]
30. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350 [TBL] [Abstract][Full Text] [Related]
31. The budget impact of cervical cancer screening using HPV primary screening. Wright T; Huang J; Baker E; Garfield S; Hertz D; Cox JT Am J Manag Care; 2016 Mar; 22(3):e95-105. PubMed ID: 26978241 [TBL] [Abstract][Full Text] [Related]
32. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings. Campos NG; Tsu V; Jeronimo J; Mvundura M; Lee K; Kim JJ Int J Cancer; 2017 Mar; 140(6):1293-1305. PubMed ID: 27925175 [TBL] [Abstract][Full Text] [Related]
33. Cost-effective policies for cervical cancer screening. An international review. Fahs MC; Plichta SB; Mandelblatt JS Pharmacoeconomics; 1996 Mar; 9(3):211-30. PubMed ID: 10160098 [TBL] [Abstract][Full Text] [Related]
34. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation. Daniels K; McKee M J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748 [TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of the cytology laboratory and new cytology technologies in cervical cancer prevention. Raab SS; Zaleski MS; Silverman JF Am J Clin Pathol; 1999 Feb; 111(2):259-66. PubMed ID: 9930150 [TBL] [Abstract][Full Text] [Related]
36. Repeat colonoscopy every 10 years or single colonoscopy for colorectal neoplasm screening in average-risk Chinese: a cost-effectiveness analysis. Wang ZH; Gao QY; Fang JY Asian Pac J Cancer Prev; 2012; 13(5):1761-6. PubMed ID: 22901118 [TBL] [Abstract][Full Text] [Related]
37. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries. Campos NG; Sharma M; Clark A; Lee K; Geng F; Regan C; Kim J; Resch S Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():47-56. PubMed ID: 28691334 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis. Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103 [TBL] [Abstract][Full Text] [Related]
39. [Costs and effects of alternative screening programs against cervical cancer]. Gyrd-Hansen D; Hølund B; Andersen P Ugeskr Laeger; 1996 Aug; 158(35):4912-5. PubMed ID: 8801698 [TBL] [Abstract][Full Text] [Related]
40. Cost effectiveness of colorectal cancer screening in the elderly. Wagner JL; Herdman RC; Wadhwa S Ann Intern Med; 1991 Nov; 115(10):807-17. PubMed ID: 1929029 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]